A Single-Arm Clinical Trial of Fuyuan Tiansui Decoction in the Treatment of Cerebellar Ataxia Syndrome
10.16466/j.issn1005-5509.2025.03.003
- VernacularTitle:复元填髓方治疗小脑共济失调综合征的单臂临床试验
- Author:
Sheng ZHAO
1
;
Kaiwen YAN
;
Juwei WANG
Author Information
1. 浙江中医药大学附属温州中西医结合医院 浙江,温州 325000
- Publication Type:Journal Article
- Keywords:
Fuyuan Tiansui Decoction;
hereditary cerebellar ataxia;
multiple system atrophy-cerebellar type;
sporadic adult-onset ataxia;
syndrome of deficiency of kidney essence;
treating different diseases with same method;
TCM symptom scale;
single arm test
- From:
Journal of Zhejiang Chinese Medical University
2025;49(3):279-284
- CountryChina
- Language:Chinese
-
Abstract:
[Objective]To observe the efficacy of Fuyuan Tiansui Decoction in the treatment of cerebellar ataxia syndrome(CAS).[Methods]A total of 29 patients with CAS treated at Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine outpatient clinics from February to October 2024 were enrolled.All participants received Fuyuan Tiansui Decoction treatment for 12 weeks.Before and after treatment,the changes of International Cooperative Ataxia Scale(ICARS),Scale for the Assessment and Rating of Ataxia(SARA),Activities of Daily Living(ADL)score and traditional Chinese medicine(TCM)syndrome scale were compared.[Results]A total of 29 patients were enrolled,with 27 completing the 12-week treatment course(2 withdrawals).Post-treatment analysis revealed an ICARS score improvement rate of 55.6%and a stabilization rate of 25.9%.The ICARS score was 35.85±12.90 before treatment and 34.33±13.10 after treatment(P<0.05).The SARA score and TCM syndrome scale score were significantly decreased(P<0.05).During the treatment,the adverse reaction rate was 11.1%,including 3 cases of diarrhea.[Conclusion]Fuyuan Tiansui Decoction can relieve the ataxia symptoms and the syndrome of kidney deficiency and marrow deficiency in patients with CAS.
